샤르코 마리 투스병 치료 시장 : 전략적 인사이트와 예측(2026-2031년)

The Global Charcot-Marie-Tooth Disease Treatment Landscape Report is predicted to grow from USD 1.88 billion 2026 at a CAGR of 13.4% to USD 3.53 billion in 2031.

The global Charcot-Marie-Tooth (CMT) disease treatment market is witnessing steady growth as advances in genetic diagnostics, improved disease awareness, and increasing investment in rare neurological disorders continue to transform the therapeutic landscape. Charcot-Marie-Tooth disease is one of the most common inherited peripheral neuropathies, characterized by progressive muscle weakness, sensory impairment, foot deformities, and peripheral nerve degeneration. While current treatment primarily focuses on symptom management and functional rehabilitation, the emergence of disease-modifying therapies is expected to significantly reshape the market over the coming decade.

The treatment market encompasses pharmacological therapies, physical rehabilitation, occupational therapy, orthopedic devices, surgical interventions, pain management, genetic counseling, and multidisciplinary neurological care. Recent advances in molecular biology, genomics, and precision medicine have accelerated research into therapies that target the underlying genetic causes of the disease rather than simply managing symptoms. As numerous investigational therapies advance through clinical development, the market is expected to shift toward personalized treatment strategies capable of slowing disease progression and improving long-term patient outcomes.

Growing adoption of next-generation sequencing and comprehensive genetic testing has improved diagnostic accuracy, enabling earlier intervention and better patient stratification. Healthcare providers are increasingly adopting multidisciplinary care models that integrate neurologists, orthopedic specialists, physiotherapists, occupational therapists, rehabilitation experts, and genetic counselors to optimize disease management. These integrated approaches improve mobility, preserve functional independence, and enhance overall quality of life for patients.

The expanding pipeline of gene therapies, RNA-based therapeutics, neuroprotective agents, and regenerative medicine is creating significant commercial opportunities for pharmaceutical and biotechnology companies. Continued investment in clinical research, supportive regulatory initiatives for orphan diseases, and increasing patient participation in clinical trials are expected to accelerate innovation and strengthen long-term market growth.

Market Drivers

Increasing Prevalence and Diagnosis of Inherited Neurological Disorders

Improved physician awareness, expanded access to genetic testing, and greater public awareness are contributing to earlier diagnosis and increasing treatment demand.

Early diagnosis enables timely intervention and supports better long-term disease management.

Advances in Precision Medicine

Rapid progress in molecular genetics and genomic medicine is enabling the development of mutation-specific therapies.

Personalized treatment approaches are expected to improve clinical outcomes while expanding future treatment options.

Growth of Disease-Modifying Therapeutics

Pharmaceutical and biotechnology companies continue investing in gene therapies, RNA therapeutics, neuroprotective agents, and small-molecule treatments targeting the underlying mechanisms of disease.

These innovations are expected to transform the future treatment landscape beyond supportive care.

Increasing Healthcare Investment

Governments, research organizations, and private investors continue increasing funding for rare neurological disorders.

Growing financial support is accelerating clinical research, therapeutic innovation, and commercialization activities.

Expansion of Multidisciplinary Care

The increasing integration of neurology, rehabilitation medicine, orthopedic care, physiotherapy, occupational therapy, and genetic counseling is improving patient outcomes.

Comprehensive treatment models continue supporting long-term disease management.

Market Restraints

Limited Availability of Disease-Modifying Therapies

Most currently available treatments remain focused on symptom control rather than halting disease progression.

The absence of widely approved curative therapies continues to limit treatment options.

High Cost of Advanced Treatments

Emerging gene therapies, RNA therapeutics, and personalized medicines require substantial investment in research, manufacturing, and specialized delivery.

High treatment costs may limit accessibility in certain healthcare systems.

Genetic Complexity

More than one hundred genetic mutations are associated with Charcot-Marie-Tooth disease, making diagnosis and treatment development increasingly complex.

Mutation-specific therapies often require highly individualized development strategies.

Technology and Segment Insights

By Treatment Type

Physical therapy remains one of the most important components of disease management by preserving muscle strength, mobility, and functional independence.

Occupational therapy, orthopedic devices, pain management, surgical interventions, rehabilitation programs, and emerging disease-modifying therapies continue expanding the overall treatment landscape.

By Disease Type

CMT1 represents the largest treatment segment due to its relatively high prevalence among inherited demyelinating neuropathies.

CMT2, CMTX, CMT4, and other rare subtypes continue receiving increasing attention as advances in precision medicine enable more targeted therapeutic development.

By End User

Hospitals and specialty neurology centers account for the largest share of treatment delivery because of access to multidisciplinary specialists and advanced diagnostic capabilities.

Rehabilitation centers, outpatient neurological clinics, and home healthcare services continue expanding as long-term disease management becomes increasingly patient-centered.

By Distribution Channel

Hospital pharmacies remain the primary distribution channel for prescription therapies and specialized neurological treatments.

Retail pharmacies continue supporting long-term medication management, while online pharmacies are gradually expanding access through digital healthcare services.

Regional Insights

North America dominates the global Charcot-Marie-Tooth disease treatment market due to advanced healthcare infrastructure, widespread availability of genetic testing, strong investment in rare disease research, and active participation in clinical development. The region also benefits from supportive regulatory policies and increasing adoption of precision medicine.

Europe represents another major market supported by comprehensive healthcare systems, specialized neuromuscular treatment centers, collaborative research networks, and growing implementation of multidisciplinary care programs. Countries such as Germany, the United Kingdom, France, Italy, and Spain continue contributing significantly to therapeutic innovation.

Asia Pacific is expected to record the fastest market growth during the forecast period owing to expanding healthcare infrastructure, improving diagnostic capabilities, increasing awareness of inherited neurological disorders, rising healthcare expenditure, and growing biotechnology investment across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually strengthening treatment availability through healthcare modernization, improved access to specialist neurological services, expanding rehabilitation programs, and increasing participation in international clinical research.

Competitive and Strategic Outlook

The global Charcot-Marie-Tooth disease treatment market is becoming increasingly competitive as pharmaceutical companies, biotechnology firms, rehabilitation providers, and healthcare organizations expand investment in innovative therapeutic solutions. Competition is shifting from traditional supportive care toward the development of disease-modifying therapies capable of addressing the underlying genetic causes of the disease.

Organizations continue investing in gene therapy, RNA therapeutics, precision medicine, biomarker discovery, regenerative medicine, and advanced diagnostic technologies. Strategic collaborations, licensing agreements, mergers and acquisitions, clinical research partnerships, and orphan drug development initiatives continue accelerating therapeutic innovation while strengthening market positioning.

Future competition is expected to focus on personalized treatment strategies, advanced genetic therapies, digital patient monitoring, multidisciplinary care integration, and technologies capable of improving mobility, slowing disease progression, and enhancing patient quality of life.

Conclusion

The global Charcot-Marie-Tooth disease treatment market is expected to maintain steady growth throughout the forecast period as advances in genetic medicine, precision diagnostics, rehabilitation technologies, and disease-modifying therapies continue transforming patient care. Increasing awareness, expanding investment in rare neurological disorders, supportive regulatory initiatives, and a robust clinical development pipeline are expected to drive sustained market expansion. Although challenges related to treatment costs, genetic complexity, and the limited availability of curative therapies remain, ongoing scientific innovation and strategic collaboration are expected to significantly improve treatment outcomes and long-term disease management for individuals living with Charcot-Marie-Tooth disease.

Key Benefits of this Report

• Insightful Analysis: Comprehensive evaluation of treatment trends, therapeutic innovations, patient management strategies, and regional market dynamics.
• Competitive Landscape: Understand strategic initiatives, product development activities, and competitive positioning across the treatment market.
• Market Drivers and Future Trends: Assess emerging therapies, precision medicine developments, and future growth opportunities.
• Actionable Recommendations: Support product development, commercialization, investment, and market entry strategies.
• Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, healthcare providers, investors, consultants, research organizations, and policymakers.

What Businesses Use Our Reports For

Treatment market assessment, product development strategy, commercial planning, investment analysis, competitive intelligence, clinical research planning, healthcare policy evaluation, market entry strategy, and business expansion.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Market analysis by treatment type, disease subtype, end user, distribution channel, and region
• Growth drivers, restraints, opportunities, challenges, and emerging treatment trends
• Competitive landscape, strategic developments, innovation pipeline, and market outlook
• Regional market forecasts across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Overview
  • 1.1.1 Scope and Objectives
  • 1.1.2 Research Methodology Overview
  • 1.1.3 Treatment Landscape Assessment Framework
  • 1.1.4 Key Strategic Findings
• 1.2 Treatment Landscape Snapshot
  • 1.2.1 Current Standard of Care Overview
  • 1.2.2 Emerging Therapeutic Landscape
  • 1.2.3 Development Stage Distribution
  • 1.2.4 Innovation Trends Summary
  • 1.2.5 Future Treatment Paradigm Outlook
• 1.3 Key Intelligence Highlights
  • 1.3.1 Most Advanced Therapeutic Programs
  • 1.3.2 Emerging Treatment Modalities
  • 1.3.3 Key Clinical Development Catalysts
  • 1.3.4 Strategic Growth Opportunities

2. Pipeline Overview

• 2.1 Global Treatment Landscape Overview
  • 2.1.1 Historical Evolution of CMT Therapeutics
  • 2.1.2 Current Treatment Environment
  • 2.1.3 Pipeline Expansion Trends
  • 2.1.4 Innovation Intensity Assessment
• 2.2 Pipeline Distribution by Development Phase
  • 2.2.1 Preclinical Pipeline
    • 2.2.1.1 Total Number of Assets
    • 2.2.1.2 Key Developers
    • 2.2.1.3 Emerging Technologies
  • 2.2.2 Phase I Pipeline
    • 2.2.2.1 Total Number of Assets
    • 2.2.2.2 Safety and Tolerability Programs
    • 2.2.2.3 Competitive Positioning
  • 2.2.3 Phase II Pipeline
    • 2.2.3.1 Total Number of Assets
    • 2.2.3.2 Proof-of-Concept Programs
    • 2.2.3.3 Differentiation Assessment
  • 2.2.4 Phase III Pipeline
    • 2.2.4.1 Total Number of Assets
    • 2.2.4.2 Registration-Enabling Studies
    • 2.2.4.3 Commercial Readiness
  • 2.2.5 Filed / Under Review Pipeline
    • 2.2.5.1 Regulatory Status Review
    • 2.2.5.2 Approval Timeline Expectations
    • 2.2.5.3 Launch Preparedness Assessment
• 2.3 Historical Progression Trends
  • 2.3.1 Phase Advancement Patterns
  • 2.3.2 Historical Development Timelines
  • 2.3.3 Clinical Attrition Trends
  • 2.3.4 Regulatory Success Patterns

3. Disease and Unmet Need Analysis

• 3.1 Disease Background
  • 3.1.1 Disease Definition
  • 3.1.2 Genetic Classification
  • 3.1.3 Pathophysiological Mechanisms
  • 3.1.4 Disease Progression Characteristics
• 3.2 Disease Subtype Analysis
  • 3.2.1 Charcot-Marie-Tooth Type 1
  • 3.2.2 Charcot-Marie-Tooth Type 2
  • 3.2.3 Charcot-Marie-Tooth Type 4
  • 3.2.4 X-Linked Charcot-Marie-Tooth Disease
  • 3.2.5 Rare Genetic Subtypes
• 3.3 Current Treatment Landscape
  • 3.3.1 Physical Therapy Approaches
  • 3.3.2 Orthotic and Assistive Devices
  • 3.3.3 Symptomatic Pharmacological Treatments
  • 3.3.4 Surgical Interventions
  • 3.3.5 Multidisciplinary Care Models
• 3.4 Unmet Clinical Needs
  • 3.4.1 Lack of Disease-Modifying Therapies
  • 3.4.2 Genetic Subtype-Specific Treatment Gaps
  • 3.4.3 Functional Outcome Challenges
  • 3.4.4 Long-Term Disease Management Needs
• 3.5 Future Treatment Opportunities
  • 3.5.1 Precision Medicine Opportunities
  • 3.5.2 Gene Therapy Opportunities
  • 3.5.3 RNA Therapeutic Opportunities
  • 3.5.4 Regenerative Medicine Opportunities

4. Mechanism and Modality Landscape

• 4.1 Mechanism of Action Analysis
  • 4.1.1 PMP22 Modulation Strategies
    • 4.1.1.1 Scientific Rationale
    • 4.1.1.2 Therapeutic Approaches
    • 4.1.1.3 Competitive Activity
  • 4.1.2 Gene Replacement Approaches
    • 4.1.2.1 Target Disease Subtypes
    • 4.1.2.2 Technology Platforms
    • 4.1.2.3 Competitive Benchmarking
  • 4.1.3 RNA-Based Therapeutics
    • 4.1.3.1 Antisense Oligonucleotides
    • 4.1.3.2 RNA Interference Strategies
    • 4.1.3.3 Delivery Technologies
  • 4.1.4 Neuroprotective Therapies
  • 4.1.5 Axonal Regeneration Strategies
  • 4.1.6 Myelin Repair Approaches
  • 4.1.7 Neuromuscular Function Enhancement
• 4.2 Mechanism Clustering Analysis
  • 4.2.1 Asset Distribution by Mechanism
  • 4.2.2 Competitive Density Analysis
  • 4.2.3 White Space Opportunities
  • 4.2.4 Mechanistic Risk Assessment
• 4.3 Innovation Analysis
  • 4.3.1 First-in-Class Opportunities
  • 4.3.2 Best-in-Class Candidates
  • 4.3.3 Breakthrough Innovation Assessment
  • 4.3.4 Emerging Scientific Trends
• 4.4 Modality Landscape
  • 4.4.1 Small Molecules
  • 4.4.2 Biologics
  • 4.4.3 RNA Therapeutics
  • 4.4.4 Gene Therapies
  • 4.4.5 Cell Therapies

5. Clinical Development Intelligence

• 5.1 Clinical Trial Landscape
  • 5.1.1 Active Clinical Trials
  • 5.1.2 Recruiting Studies
  • 5.1.3 Completed Studies
  • 5.1.4 Suspended and Terminated Studies
  • 5.1.5 Historical Trial Activity Trends
• 5.2 Trial Design Benchmarking
  • 5.2.1 Study Design Analysis
  • 5.2.2 Randomization Strategies
  • 5.2.3 Comparator Selection
  • 5.2.4 Blinding Methodologies
• 5.3 Endpoint Intelligence
  • 5.3.1 Functional Endpoints
  • 5.3.2 Neurological Assessments
  • 5.3.3 Biomarker Utilization
  • 5.3.4 Quality-of-Life Endpoints
  • 5.3.5 Digital Outcome Measures
• 5.4 Recruitment Intelligence
  • 5.4.1 Sample Size Benchmarking
  • 5.4.2 Enrollment Performance Analysis
  • 5.4.3 Recruitment Timelines
  • 5.4.4 Registry-Based Recruitment Strategies
  • 5.4.5 Geographic Enrollment Trends
• 5.5 Success and Failure Intelligence
  • 5.5.1 Clinical Success Drivers
  • 5.5.2 Trial Failure Analysis
  • 5.5.3 Dropout Trend Assessment
  • 5.5.4 Risk Factors by Development Phase

6. Pipeline Segmentation Analysis

• 6.1 Pipeline by Development Phase
  • 6.1.1 Preclinical Assets
  • 6.1.2 Phase I Assets
  • 6.1.3 Phase II Assets
  • 6.1.4 Phase III Assets
  • 6.1.5 Filed / Under Review Assets
• 6.2 Pipeline by Mechanism of Action
  • 6.2.1 Gene Regulation Programs
  • 6.2.2 RNA Therapeutic Programs
  • 6.2.3 Gene Therapy Programs
  • 6.2.4 Neuroprotective Programs
  • 6.2.5 Regenerative Medicine Programs
• 6.3 Pipeline by Therapeutic Modality
  • 6.3.1 Small Molecules
  • 6.3.2 Biologics
  • 6.3.3 RNA Therapeutics
  • 6.3.4 Gene Therapies
  • 6.3.5 Cell Therapies

7. Probability of Success and Risk Analysis

• 7.1 Phase Transition Probability Modeling
  • 7.1.1 Preclinical-to-Phase I Transition Probability
  • 7.1.2 Phase I-to-Phase II Transition Probability
  • 7.1.3 Phase II-to-Phase III Transition Probability
  • 7.1.4 Phase III-to-Approval Transition Probability
• 7.2 Attrition Analysis
  • 7.2.1 Attrition by Development Phase
  • 7.2.2 Attrition by Mechanism
  • 7.2.3 Attrition by Modality
  • 7.2.4 Historical Attrition Benchmarking
• 7.3 Risk Assessment Framework
  • 7.3.1 Scientific Risk Assessment
  • 7.3.2 Clinical Risk Assessment
  • 7.3.3 Regulatory Risk Assessment
  • 7.3.4 Commercial Risk Assessment
• 7.4 Risk-Adjusted Pipeline Valuation
  • 7.4.1 Asset-Level Risk Adjustment
  • 7.4.2 Portfolio Risk Assessment
  • 7.4.3 Probability-Weighted Revenue Potential
  • 7.4.4 Scenario-Based Forecasting

8. Launch Timeline and Commercial Potential

• 8.1 Regulatory Forecasting
  • 8.1.1 Expected Submission Timelines
  • 8.1.2 Expected Approval Timelines
  • 8.1.3 Key Regulatory Milestones
• 8.2 Launch Sequencing Analysis
  • 8.2.1 First-to-Market Opportunities
  • 8.2.2 Follow-On Entrant Analysis
  • 8.2.3 Competitive Launch Scenarios
• 8.3 Commercial Opportunity Assessment
  • 8.3.1 Addressable Patient Population
  • 8.3.2 Treatment Adoption Potential
  • 8.3.3 Pricing and Access Considerations
  • 8.3.4 Peak Sales Potential Assessment
• 8.4 Future Treatment Evolution
  • 8.4.1 Precision Medicine Impact
  • 8.4.2 Gene Therapy Market Impact
  • 8.4.3 Long-Term Treatment Paradigm Shift

9. Competitive Pipeline Landscape

• 9.1 Competitive Positioning Analysis
  • 9.1.1 Company Ranking Methodology
  • 9.1.2 Pipeline Strength Assessment
  • 9.1.3 Innovation Leadership Assessment
  • 9.1.4 Competitive Benchmark Matrix
• 9.2 Company-Level Competitive Intelligence
  • 9.2.1 Leading Developers
  • 9.2.2 Emerging Developers
  • 9.2.3 Academic Research Organizations
  • 9.2.4 Collaborative Research Networks
• 9.3 Asset-Level Competitive Intelligence Framework
  • 9.3.1 Individual Asset Analysis
    • 9.3.1.1 Molecule Profile
    • 9.3.1.2 Developer Company
    • 9.3.1.3 Mechanism of Action
    • 9.3.1.4 Clinical Development Phase
    • 9.3.1.5 Target Indication
    • 9.3.1.6 Clinical Trial Status
    • 9.3.1.7 Differentiation Assessment
    • 9.3.1.8 Competitive Threat Analysis
• 9.4 Competitive Dynamics
  • 9.4.1 Leader vs Challenger Assessment
  • 9.4.2 Innovation Competition Analysis
  • 9.4.3 Strategic Positioning Matrix
  • 9.4.4 Future Competitive Outlook

10. Geographic Analysis

• 10.1 North America
  • 10.1.1 Clinical Trial Activity
  • 10.1.2 Regulatory Speed
  • 10.1.3 Innovation Hubs
  • 10.1.4 Sponsor Presence
• 10.2 Europe
  • 10.2.1 Clinical Trial Activity
  • 10.2.2 Regulatory Speed
  • 10.2.3 Innovation Hubs
  • 10.2.4 Sponsor Presence
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Trial Activity
  • 10.3.2 Regulatory Speed
  • 10.3.3 Innovation Hubs
  • 10.3.4 Sponsor Presence
• 10.4 Latin America
  • 10.4.1 Clinical Trial Activity
  • 10.4.2 Regulatory Speed
  • 10.4.3 Innovation Hubs
  • 10.4.4 Sponsor Presence
• 10.5 Middle East & Africa
  • 10.5.1 Clinical Trial Activity
  • 10.5.2 Regulatory Speed
  • 10.5.3 Innovation Hubs
  • 10.5.4 Sponsor Presence

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Clinical Trial Activity
  • 11.1.2 Regulatory Timelines
  • 11.1.3 Key Sponsors
  • 11.1.4 Treatment Innovation Ecosystem
• 11.2 Canada
  • 11.2.1 Clinical Trial Activity
  • 11.2.2 Regulatory Timelines
  • 11.2.3 Key Sponsors
  • 11.2.4 Treatment Innovation Ecosystem
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Deals and Investment Landscape

• 12.1 Licensing Activity
  • 12.1.1 Asset Licensing Agreements
  • 12.1.2 Platform Technology Licensing
  • 12.1.3 Regional Commercialization Agreements
• 12.2 Co-Development Partnerships
  • 12.2.1 Industry Collaborations
  • 12.2.2 Academic Partnerships
  • 12.2.3 Research Consortium Activities
• 12.3 Mergers and Acquisitions
  • 12.3.1 Asset Acquisitions
  • 12.3.2 Company Acquisitions
  • 12.3.3 Strategic Consolidation Trends
• 12.4 Funding Landscape
  • 12.4.1 Venture Capital Funding
  • 12.4.2 Private Equity Investments
  • 12.4.3 Public Market Financing
  • 12.4.4 Rare Disease Grant Funding
• 12.5 Investment Intelligence
  • 12.5.1 Investment by Modality
  • 12.5.2 Investment by Development Phase
  • 12.5.3 Capital Deployment Trends
  • 12.5.4 Future Funding Outlook

13. Future Outlook and Strategic Insights

• 13.1 Future Treatment Landscape
  • 13.1.1 Emerging Scientific Approaches
  • 13.1.2 Next-Generation Therapeutic Platforms
  • 13.1.3 Precision Medicine Evolution
  • 13.1.4 Biomarker-Driven Treatment Development
• 13.2 Competitive Outlook
  • 13.2.1 Expected Future Market Leaders
  • 13.2.2 Emerging Challengers
  • 13.2.3 Competitive Threat Assessment
  • 13.2.4 Strategic Advantage Drivers
• 13.3 Strategic Opportunity Assessment
  • 13.3.1 White Space Opportunities
  • 13.3.2 Partnership Opportunities
  • 13.3.3 Geographic Expansion Opportunities
  • 13.3.4 Technology Platform Opportunities
• 13.4 Long-Term Forecast
  • 13.4.1 Five-Year Treatment Landscape Outlook
  • 13.4.2 Ten-Year Innovation Outlook
  • 13.4.3 Future Standard-of-Care Evolution

14. Methodology and Data Framework

• 14.1 Research Methodology
  • 14.1.1 Primary Research Sources
  • 14.1.2 Secondary Research Sources
  • 14.1.3 Data Validation Methodology
• 14.2 Asset Verification Framework
  • 14.2.1 ClinicalTrials.gov Validation
  • 14.2.2 EU Clinical Trials Register Validation
  • 14.2.3 Company Pipeline Verification
  • 14.2.4 Regulatory Filing Verification
• 14.3 Competitive Intelligence Framework
  • 14.3.1 Company Benchmarking Methodology
  • 14.3.2 Asset Ranking Methodology
  • 14.3.3 Competitive Scoring System
• 14.4 Forecasting Framework
  • 14.4.1 Probability of Success Methodology
  • 14.4.2 Risk Adjustment Methodology
  • 14.4.3 Revenue Potential Modeling
  • 14.4.4 Scenario Planning Framework
• 14.5 Appendix
  • 14.5.1 Verified Pipeline Asset Inventory
  • 14.5.2 Clinical Trial Database
  • 14.5.3 Treatment Modality Benchmark Tables
  • 14.5.4 Regulatory Designation Summary
  • 14.5.5 Competitive Benchmark Matrices
  • 14.5.6 Abbreviations and Definitions
  • 14.5.7 Source Validation Documentation